Overview

Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas

Status:
RECRUITING

Trial end date:
2029-09-01

Target enrollment:

Participant gender:

Summary

This research is being done to test a new drug called PEEL-224 in combination with two commercially available drugs, Vincristine and Temozolomide, and to determine how effective this combination of drugs is at treating Ewing Sarcoma (EWS) and Desmoplastic Small Round Cell Tumor (DSRCT), as well as multiple other kinds of sarcomas. The names of the study drugs and biological agents involved in this study are: * PEEL-224 (a type of Topoisomerase 1 inhibitor) * Vincristine (A type of vinca alkaloid) * Temozolomide (A type of alkylating agent) * Pegfilgrastim or Filgrastim (types of Myeloid growth factors)

Phase:

PHASE1

Details

Lead Sponsor:

David S Shulman, MD

Collaborator:

Peel Therapeutics Inc

Treatments:

Filgrastim
Granulocyte Colony-Stimulating Factor
pegfilgrastim
pegylated granulocyte colony-stimulating factor
Temozolomide
Vincristine